Drug Profile
Research programme: cancer metastases therapies - MetaSignal Therapeutics
Alternative Names: MST-100 series; MST-200 series; MST-300 series; MST-400 series; MST-500 seriesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator MetaSignal Therapeutics
- Class Antibodies; Small molecules
- Mechanism of Action Enzyme inhibitors; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer metastases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer-metastases in Canada
- 07 Mar 2012 Preclinical trials in Cancer metastases in Canada (unspecified route)